Bayesian statistical approaches to drug product variability assessment and release
Qing Cai1, Linas Mockus2, David LeBlond3
1Lachman Institute for Pharmaceutical Analysis, Long Island University, 75 Dekalb Avenue, Brooklyn, NY 11201-8423, United States.
Bayesian models enhance pharmaceutical quality control by integrating prior knowledge for predictive analysis, improving risk-based decisions and lot release strategies. This adaptive approach offers a path toward more robust quality management in drug development.
Area of Science:
- Pharmaceutical Sciences
- Statistics
- Regulatory Science
Background:
- Establishing pharmaceutical product quality is challenged by variability in critical dosage form attributes.
- Early development relies on ad hoc statistical tools to vet Critical Quality Attributes (CQAs).
- Increased process understanding near product launch allows for predictive modeling.
Purpose of the Study:
- To review a project integrating adaptive lot release with data generation and curation.
- To extend the testing of this adaptive approach.
- To discuss utility in product development and regulatory compliance.
Main Methods:
- Utilizing Bayesian models for predictive analysis and risk-based decision-making.
- Integrating prior knowledge into experimental design and analysis.
- Reviewing a joint university-FDA funded project.
Main Results:
- Bayesian models coherently integrate prior knowledge for predictive analysis.
- The Bayesian paradigm allows probability assignment to states impacting safety and efficacy.
- The reviewed project demonstrates an adaptive approach to lot release.
Conclusions:
- Bayesian predictive modeling offers a robust framework for pharmaceutical quality management.
- Challenges and reluctance exist in adopting predictive modeling post-regulatory approval.
- The paper encourages the switch to predictive modeling for industry and regulatory stakeholders.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
08:06Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays
Published on: November 10, 2016
Related Concept Videos
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
01:12Analysis of Population Pharmacokinetic Data
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
01:14Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.